AnodyneWiki

Apomorphine

Apomorphine
Apomorphine
Salts
[]
Apomorphine dihydrochloride
Apomorphine dihydrochloride
Apomorphine hydrochloride
Apomorphine hydrochloride
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass267.32 g/mol [1]
AppearanceHexagonal plates from chloroform+petroleum ether; rods from ether [1]
Melting point195 °C (decomposes) [1]
DecompositionWhen heated to decomposition it emits highly toxic fumes of nitroxides. [1]
SolubilityMINUTE, WHITE OR GRAYISH WHITE, GLISTENING CRYSTALS OR WHITE POWDER; ODORLESS; SOLN ARE NEUTRAL TO LITMUS; LEVOROTATORY IN DIL ACID; 1 G SOL IN 50 ML WATER, IN ABOUT 50 ML ALCOHOL, & IN ABOUT 20 ML WATER @ 80 °C; PPT BY TANNIC ACID & OTHER ALKALOIDAL PRECIPITANTS & DECOMP BY OXIDIZING AGENTS. /HCL/ [1]
Predicted LogP2.3 [1]
Structural Identifiers
[]
Molecular formulaC17H17NO2
IUPAC name(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
SMILESCN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O
InChIInChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1
InChIKeyVMWNQDUVQKEIOC-CYBMUJFWSA-N
CAS number58-00-4
UNIIN21FAR7B4S
PubChem CID6005
Pharmacokinetics[]
Onset10–20 min
Elimination half-life40 minutes
Duration of action60–90 min
MetabolismLiver, phase II
ExcretionLiver
Routes of administrationSubcutaneous, sublingual
Toxicity
[]
Mouse:
- oral: 300 mg/kg
- ip: 160 mg/kg
- iv: 56 mg/kg
- Intraperitoneal: 0.6 mmoles/kg
 [1]

Apomorphine (also known as L-Apomorphine, Apomorfin, Apomorphin, R-(-)-Apomorphine, Ixense, (-)-Apomorphine, 6aβ-Aporphine-10,11-diol, Apomorphinum, (-)-10,11-Dihydroxyaporphine or Vr-040) is a substance of the 1,2-diarylethylamine class.

Chemistry

Salts []

Apomorphine is typically found in the form of its dihydrochloride and hydrochloride salts.

 []

Apomorphine is a single defined stereoisomer (optical activity ( - )).

Apomorphine matches Lipinski's rule of five.

Pharmacology

Mechanism of action []

Apomorphine is a non-ergoline dopamine agonist with high binding affinity to dopamine D2, D3, and D5 receptors. Stimulation of D2 receptors in the caudate-putamen, a region of the brain responsible for locomotor control, may be responsible for apomorphine's action. However, the means by which the cellular effects of apomorphine treat hypomobility of Parkinson's remain unknown. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

shared target188
shared target23

Medical side effects []

52 side effects listed on drug labels in (apomorphine).

  • Yawning
  • Somnolence
  • Dyskinesia
  • Nausea
  • Vomiting
  • Dizziness
  • Syncope
  • Orthostatic hypotension
  • Nasopharyngitis
  • Rhinorrhoea
  • Contusion
  • Angina pectoris
  • Chest pain
  • Confusional state
  • Feeling abnormal
  • Oedema
  • Hallucination
  • Swelling
  • Granuloma
  • Pruritus
  • Anxiety
  • Arthralgia
  • Musculoskeletal discomfort
  • Asthenia
  • Fatigue
  • Back pain
  • Mental disorder
  • Constipation
  • Dehydration
  • Diarrhoea
  • Dyspnoea
  • Ecchymosis
  • Flushing
  • Headache
  • Cardiac failure congestive
  • Hypotension
  • Libido increased
  • Disturbance in sexual arousal
  • Pain in extremity
  • Pallor
  • Pathological gambling
  • Pneumonia
  • Priapism
  • Psychotic disorder
  • Shock
  • Loss of consciousness
  • Urinary tract infection
  • Injection site reaction
  • Hypersexuality
  • Hyperhidrosis
  • Parkinson's disease
  • Insomnia

Indications

  • Parkinson's disease

Subjective effects []

emily / Apomorphine []
Routes:
  • Oral (8 - 20mg)

 []

  • Australia: Apomorphine is a Schedule 4.[3]
  • Canada: Apomorphine is Prescription only.
  • United Kingdom: Apomorphine is Prescription only.
  • United States: Apomorphine is Prescription only.[4]
  • Other: Apomorphine is a Rx-only.

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 6005, Apomorphine. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/6005
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Apomorphine. UNII: N21FAR7B4S. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/N21FAR7B4S
  3. Movapo Pod (Stada Pharmaceuticals Australia Pty Ltd). Therapeutic Goods Administration (TGA). 13 September 2024. https://www.tga.gov.au/resources/prescription-medicines-registrations/movapo-pod-stada-pharmaceuticals-australia-pty-ltd
  4. Onapgo- apomorphine hydrochloride injection, solution. DailyMed. 28 February 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3552b6e-5ae7-4993-aa1a-e399c4a7080a

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 06:18:09
drugspromissing (no DrugsPRO reagent data)2026-11-20 06:18:05
erowidmissing (no Erowid substance of that name)2026-11-20 06:18:05
gsrsok2026-11-20 06:18:07
hmdbmissing (hmdb.ca refused automated access to HMDB0014852)2026-11-20 06:18:05
keggok2026-11-20 06:18:08
pubchemok2026-11-20 06:18:04
redditmissing (no r/tripreports posts mention it)2026-11-20 06:18:05
siderok2026-11-20 06:18:05
structureok2026-11-20 06:18:05
wikipediaok2026-11-20 06:18:05